You just read:

Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain

News provided by

Nektar Therapeutics

Jul 24, 2012, 08:00 ET